1-20 of 624 results for askedby:"Neale Hanvey"
Librarians' tools
- Search time
- 0.365 seconds
- Solr query time
- 0.004 seconds
- Search query
- askedby:"Neale Hanvey"
- We searched for
- tablingMember_ses:464943 OR askingMember_ses:464943
Type
House
Session
Year
Department
More
Member
More
Primary member
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
If he will make a statement on his departmental responsibilities.
If he will make a statement on his departmental responsibilities.
It is an unavoidable fact that the United Kingdom has one of the lowest pensions in the developed world, and pensioner poverty is a very real issue. I meet constituents who are pensioners reasonably frequently, and all the increases that the Government have provided for them have been lost through taxation. For example, Peter’s private pension will be cut by £681 a year, while Mr and Mrs Clark’s modest private pension has been slashed by nearly 50%. They did the right thing and put away a little extra for their retirement; will the Government now do the right thing and correct the position so that they can enjoy it?
It is an unavoidable fact that the United Kingdom has one of the lowest pensions in the developed world, and pensioner poverty is a very real issue. I meet constituents who are pensioners reasonably frequently, and all the increases that the Government have provided for them have been lost through taxation. For example, Peter’s private pension will be cut by £681 a year, while Mr and Mrs Clark’s modest private pension has been slashed by nearly 50%. They did the right thing and put away a little extra for their retirement; will the Government now do the right thing and correct the position so that they can enjoy it?
Let me simply point to what the Resolution Foundation had to say in its Living Standards Outlook: pensioner poverty is forecast to fall.
What recent assessment he has made of the potential merits of providing compensation to women born in the 1950s affected by changes to the State Pension age.
What recent assessment he has made of the potential merits of providing compensation to women born in the 1950s affected by changes to the State Pension age.
The ombudsman’s report has been laid before Parliament and it is under active and considerable consideration at the present time.
A report in today’s Scottish Daily Express notes that seven in 10 members of the public support financial compensation for women born in the 1950s. If the Government will not act on the final report of the Parliamentary and Health Service Ombudsman, which recommended compensation, will they now listen to the voice of the people and provide the proper financial redress that the Women Against State Pension Inequality absolutely deserve and are entitled to?
A report in today’s Scottish Daily Express notes that seven in 10 members of the public support financial compensation for women born in the 1950s. If the Government will not act on the final report of the Parliamentary and Health Service Ombudsman, which recommended compensation, will they now listen to the voice of the people and provide the proper financial redress that the Women Against State Pension Inequality absolutely deserve and are entitled to?
There are a variety of opinions as to what the outcome of the ombudsman’s report should be. There are the ombudsman’s recommendations themselves, to which some people take a counter-view while others believe that there should be more by way of payments. We are potentially looking at very large sums indeed. It is important, therefore, and only fair to those on all sides of the argument, that we take an appropriate amount of time to consider the report thoroughly, which the ombudsman has also invited Parliament to consider.
What recent discussions she has had with the Scottish Government on the promotion of Scottish products in overseas markets.
What recent discussions she has had with the Scottish Government on the promotion of Scottish products in overseas markets.
My Department works closely with the Scottish Government and their agencies to promote Scottish products in overseas markets. We have recently delivered
our Made in Scotland, Sold to the World exporter roadshow in Glasgow. On top of that, I am pleased to say that the PG Paper Company, a brilliant Scottish business, has just received an award in this year’s Made in the UK, Sold to the World awards.
The value of Scotland’s oil exports to the EU reached £9.4 billion in 2023, with total oil exports up 14.7%, so the value of oil as an export commodity cannot be overstated. Those billions of pounds in exports can be balanced against the modest £80 million investment that would increase Grangemouth’s profitability threefold, secure its long-term future and save Grangemouth from closure. Does the Secretary of State accept that it would be absurd for Scotland to be the only major oil-producing nation without a refinery capacity, and will she agree to meet me to discuss this matter further, given that the Scottish Government are otherwise occupied?
The value of Scotland’s oil exports to the EU reached £9.4 billion in 2023, with total oil exports up 14.7%, so the value of oil as an export commodity cannot be overstated. Those billions of pounds in exports can be balanced against the modest £80 million investment that would increase Grangemouth’s profitability threefold, secure its long-term future and save Grangemouth from closure. Does the Secretary of State accept that it would be absurd for Scotland to be the only major oil-producing nation without a refinery capacity, and will she agree to meet me to discuss this matter further, given that the Scottish Government are otherwise occupied?
The hon. Gentleman is right to raise this issue. It is something that we are concerned about and the UK and Scottish Governments are working together to understand all the options for the future of the refinery, and working closely on the issue through forums such as the Grangemouth Future Industry Board. I am very happy to meet him—as are other Ministers—to discuss this matter further.
If she will make a statement on her departmental responsibilities.
If she will make a statement on her departmental responsibilities.
The Cass review has established that social transitioning is not a neutral act, and that it introduces significant risk of harm. Does the Secretary of State agree with me that when a new First Minister emerges in Scotland, they should commit to factual, science-based education in schools and implement the Cass review findings in full, so they do not suffer the same fate as their predecessor?
The Cass review has established that social transitioning is not a neutral act, and that it introduces significant risk of harm. Does the Secretary of State agree with me that when a new First Minister emerges in Scotland, they should commit to factual, science-based education in schools and implement the Cass review findings in full, so they do not suffer the same fate as their predecessor?
I would encourage our friends and colleagues in the Scottish Government, whoever they may be at the time, to pay close attention to Hilary Cass’s report. I think her work has injected some much-needed common sense into the debate, and we are very grateful to her. This Government will always put the safety of our children first, and that is why the gender questioning guidance we have produced in draft is underpinned by the important principle of parents always being involved in decisions about their children.
To ask the Secretary of State for Health and Social Care, what steps she plans to take to ensure that online pharmacies that provide medicines to patients in the UK adhere to the NHS clinical guideline on puberty-suppressing hormones or the treatment of children and adolescents who have gender (a)...
To ask the Secretary of State for Health and Social Care, what steps she plans to take to ensure that online pharmacies that provide medicines to patients in the UK adhere to the NHS clinical guideline on puberty-suppressing hormones or the treatment of children and adolescents who have gender (a)...
All community pharmacists, whether working on a high street or online, have a duty of care to their patients. We would expect pharmacists to take reasonable steps to ensure that all the medicines they dispense are against legally valid prescriptions, and appropriate for the patient under the authority of the prescriber. This includes both National Health Service prescriptions and private prescriptions. Registered pharmacy professionals and premises are independently regulated by the General Pharmaceutical Council (GPhC), and guidance has been issued for those providing services at a distance, including online pharmacies.
While pharmacists are responsible for a final clinical check, ultimately the responsibility for the product prescribed rests with the prescriber. We are looking closely at what can be done to address any loopholes in prescribing practices, including work with the GPhC to define the dispensing responsibilities of pharmacists providing private prescriptions, as recommended by the Cass Report.
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential implications for her policies of the article in the British Medical Journal entitled Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds, published on 27...
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential implications for her policies of the article in the British Medical Journal entitled Pfizer-BioNTech vaccine is “likely” responsible for deaths of some elderly patients, Norwegian review finds, published on 27...
Following the initial roll out of the COVID-19 vaccination programme in December 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) had a comprehensive surveillance strategy in place, enabling continual close monitoring of emerging safety evidence including studies, published literature, and data arising from the widespread use in the United Kingdom and globally. This included the article and Norwegian reports highlighted. The MHRA communicates safety advice based upon consideration of the totality of evidence from all relevant information sources, rather than the strengths and limitations of individual data sources.
To ask the Secretary of State for Health and Social Care, if the Medicines and Healthcare products Regulatory Agency will establish an expert review panel to investigate the cause of death for reports of suspected (i) fatal outcomes and (ii) adverse reactions in patients who have received a covid-19 vaccine.
To ask the Secretary of State for Health and Social Care, if the Medicines and Healthcare products Regulatory Agency will establish an expert review panel to investigate the cause of death for reports of suspected (i) fatal outcomes and (ii) adverse reactions in patients who have received a covid-19 vaccine.
The Medicines and Healthcare products Regulatory Agency’s (MHRA) role is to ensure that the benefits associated with a medicinal product outweigh the known risks, at the time of first authorisation and thereafter. Whilst the MHRA seeks expert advice from the Commission on Human Medicines and its expert advisory groups on the likelihood of an association between a COVID-19 vaccine and a safety concern, this is based on the totality of evidence from Yellow Card data, and relevant information from other sources. Should a new link between a medicine and a safety concern be confirmed, the MHRA will take necessary regulatory action, such as updating product information to include a warning for patients and healthcare professionals.
To ask the Secretary of State for Health and Social Care, what processes the Medicines and Healthcare products Regulatory Agency uses to determine whether a covid-19 vaccine may have caused (a) fatal outcomes and (b) adverse reactions in patients.
To ask the Secretary of State for Health and Social Care, what processes the Medicines and Healthcare products Regulatory Agency uses to determine whether a covid-19 vaccine may have caused (a) fatal outcomes and (b) adverse reactions in patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) does not assign causality at the level of individual reports, as this is not the responsibility of the MHRA, and as such a process is not held. The MHRA holds processes for cumulative analysis of Yellow Card data, as well as assessment of data from other sources, for patterns or evidence which might suggest a causal link between the vaccination and the reported reaction, alongside other relevant data. In relation to fatal reports, it is the role of a Coroner to determine the likely cause of death for an individual. The MHRA’s approach to post authorisation surveillance of COVID-19 vaccines is outlined in the published Report of the Commission on Human Medicines Expert Working Group on COVID-19 vaccine safety surveillance.
To ask the Secretary of State for Health and Social Care, how many reports have been received by the Medicines and Healthcare products Regulatory Agency on (i) fatal outcomes and (ii) adverse reactions in patients who have received a covid-19 vaccine.
To ask the Secretary of State for Health and Social Care, how many reports have been received by the Medicines and Healthcare products Regulatory Agency on (i) fatal outcomes and (ii) adverse reactions in patients who have received a covid-19 vaccine.
The Medicines and Healthcare products Regulatory Agency has received 489,004 spontaneous suspected adverse drug reaction reports relating to a COVID-19 vaccine up to and including 28 February 2024, within the United Kingdom. 2,734 of the reports were associated with a fatal outcome. Reporters are asked to submit Yellow Card reports even if they only have a suspicion that the vaccine may have caused the adverse reaction. The existence of an adverse reaction report does not necessarily mean that the vaccine has caused the reaction. Reporting rates can be influenced by many factors, including the seriousness of the adverse reactions, their ease of recognition, and the extent of the use of a particular vaccine.
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the (a) Chair and (b) Chief Executive of the Medicines and Healthcare products Regulatory Agency on its statutory function to operate a system of post marketing surveillance in the UK for (i)...
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the (a) Chair and (b) Chief Executive of the Medicines and Healthcare products Regulatory Agency on its statutory function to operate a system of post marketing surveillance in the UK for (i)...
The Medicines and Healthcare products Regulatory Agency (MHRA) fulfils the requirements set out in the Human Medicines Regulation Part 11, in respect of obligations on the licensing authority to conduct surveillance of all medicinal products, including COVID-19 vaccines.
For COVID-19 vaccines, the MHRA implemented a proactive strategy, which included prospective safety data collection, and use of a range of domestic and international data sources and methodologies. For all products, events and outcomes, each data source is assessed based on its strengths and limitations, using appropriate methodologies and, where appropriate, statistical thresholds for those data. The MHRA also work closely with public health partners in reviewing the effectiveness and impact of the vaccines, to ensure the benefits continue to outweigh any possible side effects.
The MHRA keep all available evidence under review including studies, published literature, and data arising from the widespread use of COVID-19 vaccines in the United Kingdom and globally. Ministers routinely engage with officials from the MHRA on a number of issues.
To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency has (a) requested and (b) reviewed data from the expert review panel set up by the Norwegian government into the cause of death in relation to patients who have received a...
To ask the Secretary of State for Health and Social Care, whether the Medicines and Healthcare products Regulatory Agency has (a) requested and (b) reviewed data from the expert review panel set up by the Norwegian government into the cause of death in relation to patients who have received a...
Following the initial roll out of the COVID-19 vaccination programme in December 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) had a comprehensive surveillance strategy in place, enabling continual close monitoring of emerging safety evidence, including relevant safety information from international regulators. This included engagement with the European Medicines Agency to discuss data emerging from European Member States and countries in the European Economic Area, such as Norway. The MHRA communicates safety advice based upon consideration of the totality of evidence from all relevant information sources, rather than the strengths and limitations of individual data sources.
To ask the Secretary of State for Health and Social Care, how many of the reports in relation to (a) fatal outcomes and (b) adverse reactions in patients who have received a COVID-19 vaccine received by the Medicines and Healthcare products Regulatory Agency under its statutory function to operate a...
To ask the Secretary of State for Health and Social Care, how many of the reports in relation to (a) fatal outcomes and (b) adverse reactions in patients who have received a COVID-19 vaccine received by the Medicines and Healthcare products Regulatory Agency under its statutory function to operate a...
While the Medicines and Healthcare products Regulatory Agency carefully assesses Yellow Card reports of suspected adverse reactions, including those with a fatal outcome, to determine whether additional information is required to facilitate assessment of the link between a medicine and the reported adverse event, they do not assign causality at the level of individual reports.
Cumulatively, Yellow Card data is thoroughly analysed for patterns or evidence which might suggest a causal link between the vaccination and the reported reaction, alongside other relevant data. In relation to fatal reports, it is the role of a Coroner to determine the likely cause of death for an individual.
To ask the Secretary of State for Health and Social Care, what further steps she plans to take to ensure that clinicians operating in (a) the NHS and (b) private practice adhere to the NHS clinical guideline not recommending puberty suppressing hormones as a routine commissioning option for the treatment...
To ask the Secretary of State for Health and Social Care, what further steps she plans to take to ensure that clinicians operating in (a) the NHS and (b) private practice adhere to the NHS clinical guideline not recommending puberty suppressing hormones as a routine commissioning option for the treatment...
We have always been clear that children’s safety and well-being is paramount, so we welcome this landmark decision by the National Health Service. Ending the routine prescription of puberty blockers will help ensure that care is based on evidence, expert clinical opinion and is in the best interests of the child.
We expect the private sector to follow suit. There are no private providers registered with the Care Quality Commission (CQC) to prescribe puberty blockers to children under the age of 16. If a private organisation registered with the CQC fails to meet the conditions of its registration, then the regulator can take enforcement action.
To ask the Minister for Women and Equalities, what recent discussions she has had with Cabinet colleagues on supporting the wellbeing of gay, lesbian and bisexual young people.
To ask the Minister for Women and Equalities, what recent discussions she has had with Cabinet colleagues on supporting the wellbeing of gay, lesbian and bisexual young people.
Equality Hub Ministers regularly engage with their counterparts across Government on matters relating to LGB equality. This is because this Government is committed to improving the health and well-being of young people and we recognise that gay, lesbian and bisexual young people often face specific challenges.
This is why spending for children and young people’s mental health services has increased from £841 million in 2019/20 to just over £1 billion in 2022/23.
A further £3 million of funding has also been divided between five anti-bullying organisations to tackle bullying in schools. This includes projects that target homophobic and biphobic hate-related bullying.
In October 2022, we launched a Victim Support Service for anyone affected by or at risk of conversion practices, regardless of their sexual orientation, sex or transgender identity. The helpline can provide a safe, confidential listening and information service to anyone over the age of 13.
To ask the Secretary of State for Science, Innovation and Technology, how much her Department has spent on research into carbon capture utilisation and storage in each (a) research institution and (b) science and technology cluster in (i) England, (ii) Scotland, (iii) Wales and (iv) Northern Ireland in the last...
To ask the Secretary of State for Science, Innovation and Technology, how much her Department has spent on research into carbon capture utilisation and storage in each (a) research institution and (b) science and technology cluster in (i) England, (ii) Scotland, (iii) Wales and (iv) Northern Ireland in the last...
UK Research and Innovation has a list of research in carbon capture and storage by area. It is available at https://gow.epsrc.ukri.org/NGBOChooseTTS.aspx?Mode=ResearchArea&ItemDesc=Carbon+Capture+and+Storage
The reinstatement of a direct ferry link from the Forth estuary into Europe addresses three key objectives: an environmental objective of reducing road congestion and carbon emissions from heavy goods vehicles; improving import-export resilience; and delivering economic opportunity to Scotland. Industry agrees and ferry operators stand ready to deliver a route, but the Scottish Government lack the courage to support Project Brave. What can be done to encourage the Scottish Government to invest a modest amount of pump-prime funding to realise the economic and environmental benefits that would be felt by all across the UK?
The reinstatement of a direct ferry link from the Forth estuary into Europe addresses three key objectives: an environmental objective of reducing road congestion and carbon emissions from heavy goods vehicles; improving import-export resilience; and delivering economic opportunity to Scotland. Industry agrees and ferry operators stand ready to deliver a route, but the Scottish Government lack the courage to support Project Brave. What can be done to encourage the Scottish Government to invest a modest amount of pump-prime funding to realise the economic and environmental benefits that would be felt by all across the UK?
As I said in my initial answer, the UK Government see the ferry sector as a commercial market and do not subsidise it. As the hon. Gentleman points out, however, this is a devolved matter—in Scotland, ferries are the responsibility of the Scottish Government—so he should make his protestations about that route to the SNP Government, because it is up to them to decide what to do. I totally understand that they are slightly worried; they have an undistinguished track record on ferries, with various fiascos—maybe it is because they try to get ferries that can hold motorhomes.